CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...